Tirzepatide inj.dosafe
Reading File
Finding Sources
Searching the Web
tirzepatide injection dosage schedule titration 2025
Searching PubMed
tirzepatide dosing safety
Reading File
Reading File
Here is a complete, evidence-based summary of Tirzepatide injection dosing and safety:
Tirzepatide Injection - Dosing & Safety
What it is
Tirzepatide is a dual GIP/GLP-1 receptor agonist - the first long-acting, once-weekly injectable peptide analogue engineered from native GIP with agonist activity at both GIP and GLP-1 receptors. Its half-life is ~117 hours, allowing once-weekly dosing.
- FDA approved for Type 2 Diabetes (Mounjaro) in 2022
- FDA approved for Chronic Weight Management (Zepbound) in 2023
Dosing Schedule (Stepwise Titration)
All doses are given as subcutaneous (SC) injection once weekly into the abdomen, thigh, or upper arm.
| Week | Dose |
|---|---|
| Weeks 1-4 | 2.5 mg (initiation dose - not a treatment dose) |
| Weeks 5-8 | 5 mg |
| Weeks 9-12 | 7.5 mg (if more glucose lowering needed) |
| Weeks 13-16 | 10 mg |
| Weeks 17-20 | 12.5 mg |
| Week 21+ | 15 mg (maximum dose) |
- Dose increases by 2.5 mg increments every 4 weeks
- Maintenance doses: 5 mg, 10 mg, or 15 mg once weekly
- Maximum dose: 15 mg/week
- Can take ~20 weeks to reach maximum dose
- If a weekly dose is missed and the next dose is >4 days away, give the missed dose; if <3 days to the next dose, skip and resume the regular schedule
Injection Sites & Technique
- Subcutaneous injection in the abdomen, thigh, or upper arm
- Rotate injection sites each week
- Day of the week can be changed as long as at least 72 hours (3 days) separate doses
Efficacy
- HbA1c reduction: 1.9% to 2.6% (dose-dependent) - Katzung's Pharmacology, 16th Ed.
- Weight loss: 6.2 to 12.9 kg average; up to 21.4% placebo-subtracted weight reduction at 15 mg in SURMOUNT trials - Harrison's Principles 22E (2025)
- Additional benefits: improved lipid profile, blood pressure reduction, fatty liver improvement
Safety Profile
Common adverse effects (dose-dependent, usually mild and transient):
- Nausea
- Vomiting
- Diarrhea
- Constipation
Serious risks:
| Risk | Details |
|---|---|
| Medullary thyroid carcinoma | Contraindicated in personal/family history of medullary thyroid cancer or MEN-2 syndrome (based on rodent C-cell tumor data) |
| Pancreatitis | Slightly higher rate vs. comparators (0.23 vs 0.11 per 100 patient-years); seek care for unexplained severe abdominal pain |
| Hypoglycemia | Risk increases when combined with insulin or sulfonylureas |
| Renal injury | Possible with volume depletion from GI side effects; monitor in CKD patients |
Contraindications:
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia type 2 (MEN-2)
Key Takeaways
- Always start at 2.5 mg - this is only an initiation dose to improve tolerability, not a therapeutic dose.
- Increase by 2.5 mg every 4 weeks as tolerated - do not rush titration.
- GI side effects are the primary reason for dose delays; they typically improve with time.
- Slower titration is acceptable if GI side effects are persistent at any step.
Sources: Katzung's Basic & Clinical Pharmacology, 16th Ed. | Harrison's Principles of Internal Medicine, 22nd Ed. (2025) | Goldman-Cecil Medicine | FDA prescribing information (Mounjaro/Zepbound, 2025)
Recent meta-analysis support: A 2024 systematic review and network meta-analysis (PMID 39305981) confirms tirzepatide as among the most effective agents for weight loss, and a 2024 meta-analysis including SURMOUNT-2 (PMID 38850440) confirms favorable safety profile at 5-15 mg doses.
This is a shared conversation. Sign in to Orris to start your own chat.